Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...
Kalaris Therapeutics, Inc. reported improved Q3'25 results, with a net loss of $11.9M and $77M in cash. Click here to read why KLRS stock is a Buy.
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, ...
ABC13 Houston on MSN
Woman charged after injecting patient with counterfeit filler, practicing without license: Records
Documents state that Iris Garcia assured a patient of her medical certification, but later refused to provide any ...
With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about ...
The quickly-binding biologic lonigutamab demonstrated initial success in improving signs and symptoms of thyroid eye disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback